Checkmate Pharmaceuticals, Inc.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $85 M | No. 5 | $50 to $250 million | equity | SEC | |
| Aug 2019 | $16 M | No. 4 | $10 to $50 million | equity | SEC | |
| Nov 2018 | $22 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jun 2017 | $27 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2015 | $25 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Checkmate Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2020
That is all the official record says: Checkmate Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website did not answer.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Management IX, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| venBio Global Strategic Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| venBio Global Strategic GP II, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| venBio Global Strategic GP II, Ltd. | Company | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Arthur Krieg | Executive officer | Jun 2020 |
| Barry Labinger | Executive officer | Jun 2020 |
| Charles Yon | Executive officer | Jun 2020 |
| James Wooldridge | Executive officer | Jun 2020 |
| Jonathan Lieber | Executive officer | Jun 2020 |
| Karen Brennan | Executive officer | Jun 2020 |
| Kleem Chaudhary | Executive officer | Jun 2020 |
| Jon Lieber | Executive officer | Aug 2019 |
| Art Krieg | Executive officer | Apr 2019 |
| Chuck Abdalian | Executive officer | Apr 2019 |
| David Mauro | Executive officer | Apr 2019 |
| Arthur M. Krieg | Executive officer | Jun 2017 |
| Charles M. Abdalian | Executive officer | Jun 2017 |
| Charles M. Yon | Executive officer | Jun 2017 |
| David M. Mauro | Executive officer | Jun 2017 |
| Ramani M. Varanasi | Executive officer | Jun 2017 |
| Arthur A. Krieg | Executive officer | Feb 2017 |
| Chuck A. Abdalian | Executive officer | Feb 2017 |
| Alan Fuhrman | Director | Jun 2020 |
| Arthur Krieg | Director | Jun 2020 |
| Barry Labinger | Director | Jun 2020 |
| Corey Goodman | Director | Jun 2020 |
| Keith Flaherty | Director | Jun 2020 |
| Michael Powell | Director | Jun 2020 |
| Peter Colabuono | Director | Jun 2020 |
| Robert Weisskoff | Director | Jun 2020 |
| Ben Auspitz | Director | Aug 2019 |
| Art Krieg | Director | Apr 2019 |
| Arthur M. Krieg | Director | Jun 2017 |
| Ben M. Auspitz | Director | Jun 2017 |
| Corey M. Goodman | Director | Jun 2017 |
| Michael M. Powell | Director | Jun 2017 |
| Arthur A. Krieg | Director | Feb 2017 |
| Corey A. Goodman | Director | Feb 2017 |
| Michael A. Powell | Director | Feb 2017 |
About
Biopharmaceutical company.